Abstract Since the introduction of biological agents, accumulating results have suggested that conventional size-based RECIST criteria do not enable accurate assessment of response to therapy, and that non-size-based changes in tumor morphology can be a surrogate marker for assessment of chemotherapeutic effect. The morphological response criteria are recently introduced, nonsize-based criteria for patients undergoing chemotherapy for colorectal liver metastases (CLM). These novel criteria predict pathologic response and long-term survival of patients treated with preoperative chemotherapy, with or without bevacizumab, irrespective of their RECIST response. They have been validated in patients with resectable and unresectable CLM. These criteria are difficult to apply for small metastases and can be used as an adjunct to RECIST in assessment of response to preoperative chemotherapy.
Introduction
In the era of effective chemotherapy, valid assessment of chemotherapeutic effect is necessary not only for monitoring disease progression in advanced disease but also for selecting patients who will benefit from surgery after neoadjuvant systemic therapy. Response to chemotherapy was conventionally assessed by changes in tumor size according to the Response Evaluation Criteria in Solid Tumors (RECIST) [1] [2] [3] . However, since the introduction of molecular targeted agents, it has been reported that the RECIST criteria may underestimate the response, resulting in questioning of the adequacy of traditional size-based response criteria [4] [5] [6] [7] .
New response criteria incorporating changes in tumor density on computed tomography (CT) were first described for gastrointestinal stromal tumors [8] . Similar changes were later confirmed for patients undergoing systemic therapy with bevacizumab for renal cell carcinoma [9, 10] or colorectal liver metastases (CLM) [11••] . In this manuscript, we review the significance of non-size-based response criteria for assessing response to systemic therapy in CLM.
of up to five target lesions measured before and after treatment. The percentage difference between the two measurements is used to categorize treatment effect as follows:
& complete response (CR), disappearance of all lesions; & partial response (PR), a decrease of at least 30 % in the sum of diameters of target lesions; & progressive disease (PD), an increase of at least 20 % in the sum of diameters of target lesions and an absolute increase in the sum of at least 5 mm; and & stable disease (SD), lack of change between PD and PR [1] .
Although RECIST criteria are validated and established in the assessment of tumor response to therapy, recent studies have questioned the current cut-off points categorizing response to chemotherapy [12, 13•] . Suzuki et al. reviewed 567 patients with metastastic colorectal cancer enrolled in the multicenter randomized phase III Nordic VI trial [14] and found that a 10 % decrease in tumor diameter at first follow-up CT correlated with disease-free and overall survival, irrespective of RECIST category [13•] . Similarly, De Rook et al. reported that among patients with metastatic colorectal cancer treated with cetuximab, survival was significantly better for those with KRAS wild type tumors with reduction of tumor size >9.66 % at six weeks than for all other patients [12] . These results indicate that the current cutoff values of RECIST may not apply to all patients.
Pathologic Response
In contrast with changes in tumor size after chemotherapy, it has been reported that pathologic response to chemotherapy is strongly correlated with long-term outcome for patients undergoing hepatic resection for CLM. Our group previously reported that cumulative five-year survival after resection of pre-treated CLM was 75 % for patients with complete pathologic response (no residual cancer cells), 56 % for patients with major pathologic response (1 % to 49 % residual cancer cells), and 33 % for patients with minor response (≥50 % residual cancer cells) [15] . Maru et al. showed that tumor thickness at the tumor-normal interface in resected specimens is significantly associated with both pathologic and radiographic response, and with recurrence-free survival [16] . A correlation between pathologic response and patient survival was also reported by Rubbia-Brandt et al., who reported that histological tumor regression of CLM to chemotherapy corresponds to fibrosis overgrowth and not to increased necrosis [17] .
Morphologic Response Criteria in CLM
Increasing numbers of studies on the treatment of gastrointestinal stromal tumors or renal cell carcinoma with biological agents have reported that changes in tumor density on CT and metabolic response by FDG-PET reflect response to therapy, irrespective of changes in tumor size [4] [5] [6] [8] [9] [10] . Our group observed that after preoperative chemotherapy regimens including bevacizumab, CLM undergo morphologic changes on CT, with or without changes in tumor size, and reported that morphologic response can be an alternative criterion for evaluating response to preoperative therapy of patients with CLM [11••] .
Definition
Definitions of morphologic response criteria are summarized in Table 1 . A group 1 metastasis is characterized by homogeneous low attenuation with a thin, sharply defined tumor-liver interface. A group 3 metastasis is characterized by heterogeneous attenuation and a thick, poorly defined tumor-liver interface. A group 2 metastasis has morphology that cannot be rated as 1 or 3. Morphologic response criteria are defined as optimal if the metastasis changed from a group 3 or 2 to a 1, incomplete if the group changed from 3 to 2, and none if the group had not changed (Fig. 1 ). For patients with multiple tumors, morphologic response criteria are assigned on the basis of on the response of most tumors [11••] . 
Predictors of Optimal Morphologic Response
A recent validation study using a large cohort of patients (n=209) demonstrated that morphologic changes can be observed in patients who receive chemotherapy without bevacizumab. However, the incidence of optimal morphologic response among patients treated without bevacizumab was only 12 % (12/102) whereas an optimal morphologic response was observed for 47 % (51/108) of patients treated with bevacizumab. Multivariate analysis confirmed that use of bevacizumab (odds ratio, 6.7) and pretreatment size of tumor ≤3 cm (odds ratio, 2.1) were predictive factors for optimal morphologic response to systemic chemotherapy [18••] .
Regarding the correlation between the morphologic response and RECIST, optimal morphologic response was observed for 27 out of 69 (39 %) patients with RECIST PR and 36 out of 140 (26 %) patients with RECIST SD or PD. There was no statistically significant correlation between the morphologic response and RECIST (p=0.06) [18••] .
Long-Term Outcomes
Our preliminary report [11••] showed that the optimal morphologic response is related to improved survival both for surgical patients and for patients with unresectable metastases, whereas RECIST PR fails to predict improved survival. Among patients with unresectable metastases, median overall survival was 31 months for patients with optimal response and 19 months for those with a suboptimal response (p=0.009) [11••] . Our recent validation study Fig. 1 Optimal morphologic response after systemic chemotherapy. Group 3 morphology with heterogeneous attenuation and ill-defined margin was converted to group 1 morphology with homogeneous attenuation and sharp margin after systemic chemotherapy with bevacizumab (Table 2 ).
Limitations and Future Perspective
Although the morphologic response is a sensitive predictor of postoperative outcomes, these criteria have several limitations . First, determination of morphologic response relies on high-quality CT scanning with optimal special and contrast resolution and adequate enhancement to increase the conspicuity of tumor nodules. Therefore, standardization of imaging technique is needed to apply these criteria for assessment of patients with CLM. Second, morphologic response may be difficult to assess when a tumor is very small (usually less than 1-1.5 cm), because of partial volume effect [18••] . Although conventional RECIST criteria are less sensitive than the morphologic response criteria for prediction of both pathologic response and survival, integration of morphologic criteria and RECIST may improve the accuracy of current radiologic response evaluation.
Conclusions
The criteria used to assess morphologic response to preoperative chemotherapy, with or without bevacizumab, are significantly correlated with recurrence-free and overall survival after resection of CLM. They are more sensitive than RECIST in prediction of pathologic response and patient survival. These novel response criteria can be a surrogate therapeutic endpoint for patients with CLM.
